Brief: Ryvu Therapeutics Initiates Four Phase II Clinical Trials For RVU120
Dec 12 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* INITIATES FOUR PHASE II CLINICAL TRIALS FOR RVU120
* TRIALS WITHIN BUDGET, FUNDING SECURE UNTIL Q1 2026
* RVU120 SHOWS FAVORABLE SAFETY PROFILE COMPARED TO OTHER
AML
DRUGS
* KEY EFFICACY READOUTS FOR RVU120 TRIALS EXPECTED IN H1
2025
Source text: urn:newsml:reuters.com:*:nEM1WHRhra
Further company coverage: RVU.WA
(Reporting by Gdańsk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project